Log In Sign up
The largest database of trusted experimental protocols

Plko 1 puro shc016

Manufactured by Merck Group
Visit Supplier

PLKO.1-puro SHC016 is a plasmid vector designed for the stable expression of shRNA in mammalian cells. The vector contains a puromycin resistance gene for selection of stably transduced cells.

Automatically generated - may contain errors

Lab products found in correlation

Dharmafect 1 transfection reagent, by Horizon Discovery (2 mentions) Pbabe hygro, by Addgene (2 mentions) Pbabe c src dasatinib resistant t3381 retrovirus, by Addgene (2 mentions) Trcn0000115984, by Merck Group (2 mentions)

Spelling variants of this product

PLKO.1-puro (99 citations) PLKO.1 (97 citations) SHC016 (49 citations)

2 protocols using plko 1 puro shc016

1

BCPAP DasRes Cell Genetic Manipulation

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
BCPAP DasRes cells were transduced with pBabe-hygro or pBabe-c-Src-Dasatinib-Resistant-T3381 retrovirus (Addgene plasmid 26980) and selected with hygromycin (9 (link)). shRNAs targeting p130Cas (Sigma mission TRCN0000115984, TRCN0000115985) or a scrambled control (Sigma mission pLKO.1-puro SHC016) were transduced and selected with puromycin. BCPAP DasRes cells were transfected a gene pool of 5 different siRNAs targeting c-Jun (siJUN) or nontargeting (NT) siRNA (5 nM each) using a final concentration of 0.5% Dharmafect I transfection reagent, according to manufacturer’s protocols Dharmacon (Broomfield, CO).
Kessler B.E., Mishall K.M., Kellett M.D., Clark E.G., Pugazhenthi U., Pozdeyev N., Kim J., Tan A.C, & Schweppe R.E. (2018). Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene, 38(14), 2565-2579.
+ Open protocol
+ Expand
2

Modulating c-Src and c-Jun in BCPAP DasRes Cells

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
BCPAP DasRes cells were transduced with pBabe-hygro or pBabe-c-Src-Dasatinib-Resistant-T3381 retrovirus (Addgene plasmid 26980) and selected with hygromycin (9 (link)). shRNAs targeting p130Cas (Sigma mission TRCN0000115984, TRCN0000115985) or a scrambled control (Sigma mission pLKO.1-puro SHC016) were transduced and selected with puromycin. BCPAP DasRes cells were transfected a gene pool of 5 different siRNAs targeting c-Jun (siJUN) or nontargeting (NT) siRNA (5 nM each) using a final concentration of 0.5% Dharmafect I transfection reagent, according to manufacturer’s protocols Dharmacon (Broomfield, CO).
Kessler B.E., Mishall K.M., Kellett M.D., Clark E.G., Pugazhenthi U., Pozdeyev N., Kim J., Tan A.C, & Schweppe R.E. (2018). Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene, 38(14), 2565-2579.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!